Atrial fibrillation without comorbidities

Prevalence, incidence and prognosis (from the Framingham Heart Study)

Eun Jeong Kim, Xiaoyan Yin, Joao Daniel T. Fontes, Jared W. Magnani, Steve A. Lubitz, David D. McManus, Sudha Seshadri, Ramachandran S. Vasan, Patrick T. Ellinor, Martin G. Larson, Emelia J. Benjamin, Michiel Rienstra

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background The epidemiology of atrial fibrillation (AF) without comorbidities, known as 'lone AF', is uncertain. Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a matched sample without AF. Methods We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and triggers) among the entire AF sample in Framingham Heart Study (FHS). We compared AF without comorbidities with typical AF, and age-, sex- and cohort-matched individuals without AF, using Cox proportional hazards analysis in relation to combined cardiovascular events (stroke, heart failure, myocardial infarction), and mortality. Results Of 10,311 FHS participants, 1,961 were diagnosed with incident AF, among which 173 individuals had AF without comorbidities (47% women, mean age 71±12 years). AF without comorbidities had a prevalence of 1.7% of the entire cohort, and an annual incidence of 0.5 per 1000 person-years. During a median follow-up of 9.7 years after initial AF, 137 individuals with AF without comorbidities (79.2%) died and 141 individuals developed cardiovascular events (81.5%). AF without comorbidities had significantly lower mortality (HR 0.67, 95%CI 0.55-0.81, P

Original languageEnglish (US)
Pages (from-to)138-144
Number of pages7
JournalAmerican Heart Journal
Volume177
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Fingerprint

Atrial Fibrillation
Comorbidity
Incidence
Myocardial Infarction
Mortality
Epidemiology
Cardiovascular Diseases
Heart Failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Atrial fibrillation without comorbidities : Prevalence, incidence and prognosis (from the Framingham Heart Study). / Kim, Eun Jeong; Yin, Xiaoyan; Fontes, Joao Daniel T.; Magnani, Jared W.; Lubitz, Steve A.; McManus, David D.; Seshadri, Sudha; Vasan, Ramachandran S.; Ellinor, Patrick T.; Larson, Martin G.; Benjamin, Emelia J.; Rienstra, Michiel.

In: American Heart Journal, Vol. 177, 01.07.2016, p. 138-144.

Research output: Contribution to journalArticle

Kim, EJ, Yin, X, Fontes, JDT, Magnani, JW, Lubitz, SA, McManus, DD, Seshadri, S, Vasan, RS, Ellinor, PT, Larson, MG, Benjamin, EJ & Rienstra, M 2016, 'Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study)', American Heart Journal, vol. 177, pp. 138-144. https://doi.org/10.1016/j.ahj.2016.03.023
Kim, Eun Jeong ; Yin, Xiaoyan ; Fontes, Joao Daniel T. ; Magnani, Jared W. ; Lubitz, Steve A. ; McManus, David D. ; Seshadri, Sudha ; Vasan, Ramachandran S. ; Ellinor, Patrick T. ; Larson, Martin G. ; Benjamin, Emelia J. ; Rienstra, Michiel. / Atrial fibrillation without comorbidities : Prevalence, incidence and prognosis (from the Framingham Heart Study). In: American Heart Journal. 2016 ; Vol. 177. pp. 138-144.
@article{8245513b9640481fa6962f3ac49124b3,
title = "Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study)",
abstract = "Background The epidemiology of atrial fibrillation (AF) without comorbidities, known as 'lone AF', is uncertain. Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a matched sample without AF. Methods We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and triggers) among the entire AF sample in Framingham Heart Study (FHS). We compared AF without comorbidities with typical AF, and age-, sex- and cohort-matched individuals without AF, using Cox proportional hazards analysis in relation to combined cardiovascular events (stroke, heart failure, myocardial infarction), and mortality. Results Of 10,311 FHS participants, 1,961 were diagnosed with incident AF, among which 173 individuals had AF without comorbidities (47{\%} women, mean age 71±12 years). AF without comorbidities had a prevalence of 1.7{\%} of the entire cohort, and an annual incidence of 0.5 per 1000 person-years. During a median follow-up of 9.7 years after initial AF, 137 individuals with AF without comorbidities (79.2{\%}) died and 141 individuals developed cardiovascular events (81.5{\%}). AF without comorbidities had significantly lower mortality (HR 0.67, 95{\%}CI 0.55-0.81, P",
author = "Kim, {Eun Jeong} and Xiaoyan Yin and Fontes, {Joao Daniel T.} and Magnani, {Jared W.} and Lubitz, {Steve A.} and McManus, {David D.} and Sudha Seshadri and Vasan, {Ramachandran S.} and Ellinor, {Patrick T.} and Larson, {Martin G.} and Benjamin, {Emelia J.} and Michiel Rienstra",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.ahj.2016.03.023",
language = "English (US)",
volume = "177",
pages = "138--144",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Atrial fibrillation without comorbidities

T2 - Prevalence, incidence and prognosis (from the Framingham Heart Study)

AU - Kim, Eun Jeong

AU - Yin, Xiaoyan

AU - Fontes, Joao Daniel T.

AU - Magnani, Jared W.

AU - Lubitz, Steve A.

AU - McManus, David D.

AU - Seshadri, Sudha

AU - Vasan, Ramachandran S.

AU - Ellinor, Patrick T.

AU - Larson, Martin G.

AU - Benjamin, Emelia J.

AU - Rienstra, Michiel

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background The epidemiology of atrial fibrillation (AF) without comorbidities, known as 'lone AF', is uncertain. Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a matched sample without AF. Methods We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and triggers) among the entire AF sample in Framingham Heart Study (FHS). We compared AF without comorbidities with typical AF, and age-, sex- and cohort-matched individuals without AF, using Cox proportional hazards analysis in relation to combined cardiovascular events (stroke, heart failure, myocardial infarction), and mortality. Results Of 10,311 FHS participants, 1,961 were diagnosed with incident AF, among which 173 individuals had AF without comorbidities (47% women, mean age 71±12 years). AF without comorbidities had a prevalence of 1.7% of the entire cohort, and an annual incidence of 0.5 per 1000 person-years. During a median follow-up of 9.7 years after initial AF, 137 individuals with AF without comorbidities (79.2%) died and 141 individuals developed cardiovascular events (81.5%). AF without comorbidities had significantly lower mortality (HR 0.67, 95%CI 0.55-0.81, P

AB - Background The epidemiology of atrial fibrillation (AF) without comorbidities, known as 'lone AF', is uncertain. Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a matched sample without AF. Methods We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and triggers) among the entire AF sample in Framingham Heart Study (FHS). We compared AF without comorbidities with typical AF, and age-, sex- and cohort-matched individuals without AF, using Cox proportional hazards analysis in relation to combined cardiovascular events (stroke, heart failure, myocardial infarction), and mortality. Results Of 10,311 FHS participants, 1,961 were diagnosed with incident AF, among which 173 individuals had AF without comorbidities (47% women, mean age 71±12 years). AF without comorbidities had a prevalence of 1.7% of the entire cohort, and an annual incidence of 0.5 per 1000 person-years. During a median follow-up of 9.7 years after initial AF, 137 individuals with AF without comorbidities (79.2%) died and 141 individuals developed cardiovascular events (81.5%). AF without comorbidities had significantly lower mortality (HR 0.67, 95%CI 0.55-0.81, P

UR - http://www.scopus.com/inward/record.url?scp=84971326404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971326404&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2016.03.023

DO - 10.1016/j.ahj.2016.03.023

M3 - Article

VL - 177

SP - 138

EP - 144

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -